© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 23, 1787-1794,
December 6, 1995
© 1995 Oxford University Press
Inhibition of Growth of Human Osteosarcomas by Antagonists of Growth Hormone-Releasing Hormone
Endocrine, Polypeptide, and Cancer Institute, Department of Veterans Affairs Medical Center, and Section of Experimental Medicine, Tulane University School of Medicine New Orleans, LA.
Correspondence to: Andrew V. Schally, Ph.D., M.D.h.c, VA Medical Center, 1601 Perdido St, New Orleans, LA 70146.
Background: Insulin-like growth factor I (IGF-I) may be involved in the proliferation of human osteosarcomas. Most of the IGF-I found in blood is produced in the liver, where transcription of the IGF-I gene is regulated by growth hormone (GH). Recently, we synthesized various potent antagonists of GH-releasing hormone (GH-RH), including [Ibu0, D-Arg2, Phe(4-CI)6, Abu15, Nle27]hGH-RH(l-28)Agm, which is also called MZ-4–71. Purpose: We investigated the effects of this antagonist on the growth of the human osteosar-coma cell lines SK-ES-1 and MNNG/HOS, transplanted into nude mice or cultured in vitro. Methods: Nude male mice bearing SK-ES-1 and MNNG/HOS tumors were treated for 4 and 3 weeks, respectively, with MZ-4–71 administered from osmotic mini-pumps at a dose of 40 µg per animal per day. Tumor volume, tumor weight, and levels of receptors for IGF-I were determined. IGF-I levels in serum, tumor, and liver tissue were measured by radioimmunoassay. In other experiments, tumor-bearing nude mice were treated subcutaneous!y for 3 weeks with the GH-RH agonist hGH-RH(l-29)NH2 or with MZ-4–71 for 13 days at doses of 50 µg per animal per day. Effects of MZ-4–71, hGH-RH(l-29)NH2, and human GH (hGH) on cell proliferation and on the production of IGF-I and cyclic adenosine monophosphate were also evaluated in SK-ES-1 and MNNG/HOS cells in vitro. Results: The growth of SK-ES-1 and MNNG/HOS tumors in nude mice was significantly inhibited by MZ-4–71, as measured by a reduction in tumor volume and weight (all P values <.O5). MZ-4–71 treatment of either SK-ES-1 or MNNG/HOS tumor-bearing animals decreased tumor tissue IGF-I levels. The growth of MNNG/HOS xenografts was stimulated by hGH-RH(1–29)NH2 (P<.01). IGF-I levels in serum of tumor-bearing nude mice treated sub-cutaneously for 13 days with MZ-4–71 were decreased (both P values <.O1). High-affinity binding sites for IGF-I were demonstrated on cell membranes of SK-ES-1 and MNNG/HOS tumors. In cell cultures of both osteosarcomas, IGF-I production was stimulated by 25 ng/mL hGH but was not changed by 10 ng/mL hGH-RH(l-29)NH2 or 5 µM MZ-4–71. Incorporation of [3H]thy-midine into DNA in SK-ES-1 (but not MNNG/HOS) cells was increased by 25 ng/mL IGF-I (P<.01). The proliferation rate of the two cell lines was not affected by 5–50 ng/mL hGH-RH(l-29)NH2 or 1–80 ng/mL hGH but was suppressed by 10–6–10–5 M MZ-4-71. Conclusions: Our findings demonstrate that the GH-RH antagonist MZ-4-71 can significantly inhibit the growth of SK-ES-1 and MNNG/HOS osteosarcomas in mice.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, and G. Halmos Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel PNAS, February 6, 2007; 104(6): 1943 - 1946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Siriwardana, A. Bradford, D. Coy, and P. Zeitler Autocrine/Paracrine Regulation of Breast Cancer Cell Proliferation by Growth Hormone Releasing Hormone via Ras, Raf, and Mitogen-Activated Protein Kinase Mol. Endocrinol., September 1, 2006; 20(9): 2010 - 2019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Keller, A. V. Schally, K. Groot, G. L. Toller, A. Havt, F. Koster, P. Armatis, G. Halmos, M. Zarandi, J. L. Varga, et al. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone PNAS, July 26, 2005; 102(30): 10628 - 10633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Engel, G. Keller, A. V. Schally, G. L. Toller, K. Groot, A. Havt, P. Armatis, M. Zarandi, J. L. Varga, and G. Halmos Inhibition of Growth of Experimental Human Endometrial Cancer by an Antagonist of Growth Hormone-Releasing Hormone J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3614 - 3621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Toller, J. E. Horvath, A. V. Schally, G. Halmos, J. L. Varga, K. Groot, D. Chism, and M. Zarandi Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors PNAS, October 19, 2004; 101(42): 15160 - 15165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Szereday, A. V. Schally, J. L. Varga, C. A. Kanashiro, F. Hebert, P. Armatis, K. Groot, K. Szepeshazi, G. Halmos, and R. Busto Antagonists of Growth Hormone-Releasing Hormone Inhibit the Proliferation of Experimental Non-Small Cell Lung Carcinoma Cancer Res., November 15, 2003; 63(22): 7913 - 7919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Letsch, A. V. Schally, R. Busto, A. M. Bajo, and J. L. Varga Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers PNAS, February 4, 2003; 100(3): 1250 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Halmos, A. V. Schally, T. Czompoly, M. Krupa, J. L. Varga, and Z. Rekasi Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Human Prostate Cancer J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4707 - 4714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Busto, A. V. Schally, J. L. Varga, M. O. Garcia-Fernandez, K. Groot, P. Armatis, and K. Szepeshazi The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas PNAS, September 3, 2002; 99(18): 11866 - 11871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Khanna, J. Prehn, D. Hayden, R. D. Cassaday, J. Caylor, S. Jacob, S. M. Bose, S.-H. Hong, S. M. Hewitt, and L. J. Helman A Randomized Controlled Trial of Octreotide Pamoate Long-acting Release and Carboplatin versus Carboplatin Alone in Dogs with Naturally Occurring Osteosarcoma: Evaluation of Insulin-like Growth Factor Suppression and Chemotherapy Clin. Cancer Res., July 1, 2002; 8(7): 2406 - 2412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kiaris, A. V. Schally, R. Busto, G. Halmos, S. Artavanis-Tsakonas, and J. L. Varga Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs PNAS, January 1, 2002; (2002) 12590999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Szepeshazi, A. V. Schally, P. Armatis, K. Groot, F. Hebert, A. Feil, J. L. Varga, and G. Halmos Antagonists of GHRH Decrease Production of GH and IGF-I in MXT Mouse Mammary Cancers and Inhibit Tumor Growth Endocrinology, October 1, 2001; 142(10): 4371 - 4378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Chatzistamou, A. V. Schally, J. L. Varga, K. Groot, P. Armatis, R. Busto, and G. Halmos Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude Mice J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2144 - 2152. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Rekasi, J. L. Varga, A. V. Schally, G. Halmos, P. Armatis, K. Groot, and T. Czompoly Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers Endocrinology, June 1, 2000; 141(6): 2120 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Kineman Antitumorigenic actions of growth hormone-releasing hormone antagonists PNAS, January 18, 2000; 97(2): 532 - 534. [Full Text] [PDF]
|
|
|
|
|
|
H. Kiaris, A. V. Schally, J. L. Varga, K. Groot, and P. Armatis From the Cover: Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma PNAS, December 21, 1999; 96(26): 14894 - 14898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Csernus, A. V. Schally, H. Kiaris, and P. Armatis Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro PNAS, March 16, 1999; 96(6): 3098 - 3103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Kahán, J. M. Arencibia, V. J. Csernus, K. Groot, R. D. Kineman, W. R. Robinson, and A. V. Schally Expression of Growth Hormone-Releasing Hormone (GHRH) Messenger Ribonucleic Acid and the Presence of Biologically Active GHRH in Human Breast, Endometrial, and Ovarian Cancers J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 582 - 589. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Varga, A. V. Schally, V. J. Csernus, M. Zarandi, G. Halmos, K. Groot, and Z. Rekasi Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities PNAS, January 19, 1999; 96(2): 692 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kiaris and A. V. Schally Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone PNAS, January 5, 1999; 96(1): 226 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lamharzi, A. V. Schally, M. Koppan, and K. Groot Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors PNAS, July 21, 1998; 95(15): 8864 - 8868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jungwirth, A. V. Schally, J. Pinski, K. Groot, P. Armatis, and G. Halmos Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma PNAS, May 27, 1997; 94(11): 5810 - 5813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kiaris, A. V. Schally, R. Busto, G. Halmos, S. Artavanis-Tsakonas, and J. L. Varga Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs PNAS, January 8, 2002; 99(1): 196 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Halmos, A. V. Schally, J. L. Varga, A. Plonowski, Z. Rekasi, and T. Czompoly Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone PNAS, September 12, 2000; 97(19): 10555 - 10560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Rekasi, T. Czompoly, A. V. Schally, and G. Halmos Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers PNAS, September 12, 2000; 97(19): 10561 - 10566. [Abstract] [Full Text] [PDF]
|
|